CTOs on the Move

Cardon Outreach

www.cardonoutreach.com

 
Cardon Outreach works tirelessly to reduce the financial burden of medical bills on Americans and on the healthcare providers who serve them. Our work makes a positive difference to thousands of people and hundreds of hospitals and clinics, in communities all over the nation, every day. It is this mission that enables our success at over 800 facilities across 39 states. Over our 20+ years of service we have helped over 24 million individuals, translating into over $100 billion dollars in healthcare spend. Our technology driven, innovative approach to the revenue cycle is prepared to overcome the challenges of the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.cardonoutreach.com
  • 4185 Technology Forest Blvd Suite 200
    The Woodlands, TX USA 77381
  • Phone: 281.296.1771

Executives

Name Title Contact Details

Similar Companies

Truly Instrument Limited

Truly Instrument Limited is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeSign

LifeSign is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Typenex Medical

The Typenex® Medical advantage is connecting with our customers to understand their process needs, then to deliver simple, high-quality products that streamline workflows. Our strength is providing customers the help they need to make sure their process is successful. We think about efficiency and cost-effectiveness, along with patient safety and patient comfort, while providing a quality product. We thoroughly understand the invaluable nature of training and customer service.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.

FusionOne

FusionOne is a Roselle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.